Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Atomoxetine (Primary) ; Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacogenomic; Therapeutic Use
- 08 Sep 2015 Status changed from recruiting to completed as per data presented in the European Neuropsychopharmacology.
- 08 Sep 2015 Results published in the European Neuropsychopharmacology.
- 09 Jul 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.